financetom
Business
financetom
/
Business
/
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
Nov 20, 2024 7:41 PM

05:02 PM EST, 11/20/2024 (MT Newswires) -- (Updates the stock change in the last paragraph.)

Nvidia ( NVDA ) reported fiscal Q3 non-GAAP earnings late Wednesday of $0.81 per diluted share, up from $0.40 a year earlier.

Analysts polled by FactSet expected $0.75 excluding some items.

Revenue in the three months ended Oct. 27 rose to $35.08 billion from $18.12 billion a year earlier.

Analysts surveyed by FactSet expected $33.17 billion.

The company expects fiscal Q4 revenue of $37.5 billion, plus or minus 2%. Analysts expect $37.09 billion.

Nvidia ( NVDA ) shares fell 0.7% in after-hours activity, paring earlier losses.

Price: 144.81, Change: -1.08, Percent Change: -0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Recursion Pharmaceuticals Fiscal Q2 Loss Widens, Revenue Rises
Recursion Pharmaceuticals Fiscal Q2 Loss Widens, Revenue Rises
Aug 5, 2025
08:24 AM EDT, 08/05/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) reported fiscal Q2 loss Tuesday of $0.41 per diluted share, widening from a $0.40 loss a year earlier. Analysts polled by FactSet expected a $0.34 loss. Revenue for the quarter ended June 30 was $19.2 million, up from $14.4 million a year earlier. Analysts surveyed by FactSet expected...
Silicon Laboratories Fiscal Q2 Loss Narrows, Revenue Rises; Fiscal Q3 Guidance Issued
Silicon Laboratories Fiscal Q2 Loss Narrows, Revenue Rises; Fiscal Q3 Guidance Issued
Aug 5, 2025
08:25 AM EDT, 08/05/2025 (MT Newswires) -- Silicon Laboratories ( SLAB ) reported Tuesday its fiscal Q2 loss narrowed to $0.67 per diluted share, compared with a loss of $2.56 a year earlier. Analysts polled by FactSet expected $0.66 loss. Revenue for the quarter ended July 5 was $192.8 million, compared with $145.4 million a year earlier. Analysts surveyed by...
Ocular Therapeutix Q2 Loss Widens, Revenue Falls; Shares Down Pre-Bell
Ocular Therapeutix Q2 Loss Widens, Revenue Falls; Shares Down Pre-Bell
Aug 5, 2025
08:25 AM EDT, 08/05/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) reported a Q2 loss Tuesday of $0.39 per diluted share, compared with a loss of $0.26 a year earlier. Analysts polled by FactSet expected a loss of $0.35. Total revenue for the quarter ended June 30 was $13.5 million, down from $16.4 million a year earlier. Analysts surveyed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved